Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:3690
SEHK:3690Hospitality

Does Meituan’s Q3 2025 Swing To Net Loss Change The Bull Case For Meituan (SEHK:3690)?

Meituan has reported its third quarter 2025 results, with revenue rising slightly year-on-year to CNY 95,488.11 million but shifting from a CNY 12,864.70 million net profit to a CNY 18,632.45 million net loss. This move from profit to loss despite higher sales points to pressure on costs or margins, raising questions about the quality of Meituan’s current growth. Next, we’ll examine how Meituan’s swing to a sizeable quarterly net loss could reshape its previously margin-focused investment...
NYSE:CIVI
NYSE:CIVIOil and Gas

Is Civitas Resources a 2025 Bargain After a 36% Slide and Strong Cash Flow Outlook?

Wondering whether Civitas Resources is a value play or a value trap at today’s price? You are not alone. This stock has quietly shifted from market favorite to contrarian idea. The share price has bounced about 10.5% over the last month but is still down roughly 36.4% year to date and 33.8% over the last year, a mix that often signals either a looming problem or a mispriced opportunity. Recent headlines around Civitas have focused on its portfolio positioning and capital discipline in a...
NasdaqGS:MGPI
NasdaqGS:MGPIBeverage

MGP Ingredients (MGPI): Reassessing Valuation After Chairman’s Share Sale and Ongoing Margin Pressures

After the Chairman of the Board moved to sell a sizable block of shares, MGP Ingredients (MGPI) quickly drew fresh scrutiny as investors weighed this signal against already weakening sales and margin pressure. See our latest analysis for MGP Ingredients. The share sale comes after a rough stretch, with the share price down sharply on a year to date basis and multi year total shareholder returns deeply negative. However, this week’s double digit 7 day share price return hints at traders...
ASX:STK
ASX:STKMetals and Mining

3 ASX Penny Stocks With Market Caps Reaching A$900M

The Australian stock market has faced challenges recently, with the ASX200 underperforming compared to its global peers despite a US Fed Rate Cut. In such conditions, investors often look towards penny stocks as a potential avenue for growth. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer opportunities when they possess strong financials and clear growth prospects.
TSXV:NPTH
TSXV:NPTHHealthcare

Innovotech And 2 Other Promising Penny Stocks On The TSX

As we approach the end of 2025, Canadian markets have shown robust performance with the TSX posting a solid 27% gain year-to-date. In such a favorable market climate, identifying stocks that combine affordability with growth potential becomes crucial. Penny stocks, though often seen as relics of past market eras, continue to offer intriguing opportunities for investors who seek value in smaller or newer companies with strong financial foundations.
SWX:NWRN
SWX:NWRNPharmaceuticals

Newron Pharmaceuticals (SWX:NWRN): Evaluating Valuation After Launching ENIGMA-TRS 2 Phase III Evenamide Trial

Newron Pharmaceuticals (SWX:NWRN) just hit a key milestone by kicking off its ENIGMA TRS 2 Phase III trial in the US to test Evenamide as an add on therapy for treatment resistant schizophrenia. See our latest analysis for Newron Pharmaceuticals. That backdrop helps explain why momentum in Newron’s shares has been building, with a 30 day share price return of 39.41 percent and a 1 year total shareholder return of 157.51 percent, while the 3 year total shareholder return sits above 1,300...
NasdaqGS:HSII
NasdaqGS:HSIIProfessional Services

Heidrick & Struggles Valuation After 2025 Share Price Surge and Pending Cash Buyout Deal

If you are wondering whether Heidrick & Struggles International is still a smart buy after such a strong run, you are not alone. This is exactly what we are going to unpack here. The stock has climbed 33.9% year to date and is up 30.4% over the last year, while longer term holders have seen gains of 108.8% over 3 years and 122.8% over 5 years, all from a recent close of $59.01. Those gains have come as investors have warmed to the company’s positioning in higher value advisory and leadership...
NYSE:QXO
NYSE:QXOTrade Distributors

Three Stocks That May Be Priced Below Their Estimated Worth In December 2025

As the U.S. market navigates a complex landscape with the Dow Jones Industrial Average reaching new heights and tech-heavy indices like the Nasdaq and S&P 500 experiencing pullbacks, investors are closely watching for opportunities amid fluctuating interest rates and economic data. In this environment, identifying stocks that may be undervalued requires careful consideration of their intrinsic worth relative to current market conditions, offering potential value in a diverse portfolio.
NasdaqGS:TMCI
NasdaqGS:TMCIMedical Equipment

Talkspace Leads These 3 Promising Penny Stocks

The U.S. stock market has been experiencing mixed movements, with the Dow Jones Industrial Average recently setting a new all-time high while the Nasdaq and S&P 500 have pulled back due to concerns over tech stocks. Despite these fluctuations, certain investment opportunities continue to capture attention, particularly in areas that offer affordability and potential growth. Penny stocks, though an outdated term, still represent smaller or newer companies that can provide significant value...
NYSE:NGVT
NYSE:NGVTChemicals

Has Ingevity’s 48.8% Rally in 2025 Outpaced Its Fundamental Recovery?

Wondering if Ingevity at around $58.83 is still a smart buy or if the easy money has already been made? You are not alone; this stock has quietly been drawing fresh attention from value focused investors. After a tough few years, the share price has surged, up 12.6% over the last week, 18.8% over the past month, and 48.8% year to date, even though the 3 and 5 year returns are still down 15.5% and 19.7% respectively. Part of this turnaround story reflects shifting sentiment around specialty...